Agenus Inc.
NASDAQ•AGEN
CEO: Dr. Garo H. Armen Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2000-02-08
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Contact Information
Market Cap
$114.61M
P/E (TTM)
-3.1
17.5
Dividend Yield
--
52W High
$7.34
52W Low
$1.38
52W Range
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$30.24M+20.40%
4-Quarter Trend
EPS
$2.00-164.94%
4-Quarter Trend
FCF
-$14.74M-72.35%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Increased Modestly Nine months total revenues reached 80.0 M USD, showing a 4.4% increase from 76.6 M USD last year.
Return to Profitability Reported net income of 7.5 M USD, significantly reversing the 185.5 M USD net loss recorded previously.
Major Deconsolidation Gain Recognized 100.9 M USD gain upon deconsolidation of equity investment in MiNK Therapeutics in Q3 2025.
R&D Spending Reduced Research and development expenses decreased 53.8% to 71.8 M USD for the nine months ended September 30, 2025.
Risk Factors
Going Concern Uncertainty Substantial doubt exists regarding ability to continue as going concern for one year post-filing date.
Pending Securities Litigation Facing securities class action lawsuit; management cannot estimate range of loss from adverse decision currently.
Low Cash Reserves Cash and cash equivalents were only 3.5 M USD at September 30, 2025, necessitating immediate funding.
Manufacturing Asset Sale Closing of Zydus manufacturing asset sale, crucial for near-term liquidity, anticipated in Q1 2026.
Outlook
Secure Additional Funding Actively discussing funding to support planned registration and launch strategy for botensilimab/balstilimab.
Post-Quarter Financing Secured Entered 10.0 M USD Zydus Promissory Note and raised 4.5 M USD from ATM offerings post-quarter end.
Manufacturing Sale Closing Anticipate closing of substantially all manufacturing operations sale to Zydus in the first quarter of 2026.
Key Executive Transition VP Finance/PFO Christine Klaskin plans retirement effective December 31, 2025, continuing as consultant.
Peer Comparison
Revenue (TTM)
$106.83M
$26.87M
$16.58M
Gross Margin (Latest Quarter)
52.0%
37.6%
19.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IRD | $334.48M | -5.0 | -622.0% | 0.0% |
| CNTX | $268.29M | -10.5 | -30.9% | 0.2% |
| ZNTL | $221.09M | -1.5 | -51.5% | 11.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.1%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:Mar 16, 2026
EPS:-$1.04
|Revenue:$28.10M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data